IP Library Granted Patent US 8,137,966
Granted Patent B2
US 8,137,966 · App. 10/591,407 · Granted Mar 20, 2012

Rat embryonic stem cell

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,137,966
App. No.
10/591,407
Granted
Mar 20, 2012
Kind
B2
Abstract

The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3/4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like.

Claims (11)

1. A method of producing a rat embryonic stem cell, which method consists essentially of the following steps (A)-(E) performed using a culture medium with 2% or less serum concentration:

(A) culturing a rat blastocyst on inactivated mouse embryonic fibroblasts in a leukemia inhibitory factor (LIF)-free culture medium to form an inner cell mass in the blastocyst,

(B) dissociating the inner cell mass, wherein the dissociated inner cell mass is in a cell aggregate state,

(C) culturing primary embryonic stem cells resulting from a culture of the dissociated inner cell mass on inactivated mouse embryonic fibroblasts until the primary embryonic stem cells can be passaged,

(D) dissociating the primary embryonic stem cells, which can be passaged, wherein the dissociated primary embryonic stem cells are in a cell aggregate state, and

(E) culturing the dissociated primary embryonic stem cells on inactivated mouse embryonic fibroblasts to establish an embryonic stem cell,

wherein a rat leukemia inhibitory factor (rLIF)-containing culture medium is used in steps (C)-(E).

2. The method of claim 1 , wherein the culture medium comprises a serum replacement reagent.

3. The method of claim 1 , wherein step (B) comprises a step for mechanically dissociating the inner cell mass.

4. The method of claim 1 , wherein step (D) comprises a step for mechanically dissociating the embryonic stem cells.

5. The method of claim 1 , wherein a leukemia inhibitory factor (LIF)-free culture medium is used in step (B).

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2019
From: DS PHARMA BIOMEDICAL CO., LTD.
To: SUMITOMO CHEMICAL COMPANY, LIMITED
Reel/Frame 048724/0360 →
ADDRESS CHANGE Recorded Nov 28, 2017
From: DS PHARMA BIOMEDICAL CO., LTD.
To: DS PHARMA BIOMEDICAL CO., LTD.
Reel/Frame 044514/0891 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2016
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: DS PHARMA BIOMEDICAL CO., LTD.
Reel/Frame 039759/0163 →
CHANGE OF NAME Recorded Aug 25, 2014
From: DAINIPPON SUMITOMO PHARMA CO., LTD.
To: SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 033606/0307 →
PARTIAL ASSIGNMENT Recorded Apr 29, 2011
From: DAINIPPON SUMITOMO PHARMA CO., LTD.
To: NATIONAL CANCER CENTER
Reel/Frame 026205/0360 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2007
From: TERATANI, TAKUMI; OCHIYA, TAKAHIRO
To: DAINIPPON SUMITOMO PHARMA CO., LTD.
Reel/Frame 019302/0870 →